Provides an India-specific consensus policy framework for integrated cardiovascular-kidney-metabolic care, adapting international evidence to local epidemiology and drug access realities.
Cardiovascular disease, chronic kidney disease and metabolic dysfunction are now understood as one continuum rather than three diseases. India carries an exceptional share of that burden, yet care remains organised around organs and specialties, and fewer than one in five patients with concurrent disease receives all the protective drug classes together. Convened by the CARDIABCON Society, and informed by a structured evidence synthesis and a confirmatory modified-Delphi vote of its faculty, this Viewpoint sets out an India-specific policy framework for integrated cardiovascular–kidney–metabolic care. It is a consensus policy statement, not a clinical practice guideline. It adapts international evidence to Indian epidemiology, the observed South Asian phenotype and drug-access realities; prioritises indication-based use of SGLT2 inhibitors, GLP-1 receptor agonists and finerenone; and proposes India-specific staging, risk prediction, frugal surveillance and a national registry for prospective validation.
No takes yet. Share an insight, caveat, or question.
Mishra et al. (2026) studied Cardiovascular disease, chronic kidney disease, and metabolic dysfunction. Integrated cardiovascular-kidney-metabolic care policy framework was evaluated. An India-specific consensus policy framework was developed for integrated cardiovascular-kidney-metabolic care, prioritizing indication-based use of SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: